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Objective: Visceral artery aneurysms may be treated by aneurysm exclusion, excision, revascularization, and endovascular
techniques. The purpose of this study was to review the outcomes of the management of visceral artery aneurysms with
catheter-based techniques.
Methods: Between 1997 and 2005, 90 patients were identified with a diagnosis of visceral artery aneurysm. This was
inclusive of aneurysmal disease of the celiac axis, superior mesenteric artery (SMA), inferior mesenteric artery, and their
branches. Surveillance without intervention occurred in 23 patients, and 19 patients underwent open aneurysm repair
(4 ruptures). The endovascular treatment of 48 consecutive patients (mean age 58, 60% men) with 20 visceral artery
aneurysms (VAA) and 28 visceral artery pseudoaneurysms (VAPA) was the basis for this study. Electronic and hardcopy
medical records were reviewed for demographic data and clinical variables. Original computed tomography (CT) scans
and fluoroscopic imaging were evaluated.
Results: The endovascular treatment of visceral artery aneurysms was technically successful in 98% of 48 procedures,
consisting of 3 celiac axis repairs, 2 left gastric arteries, 1 SMA, 12 hepatic arteries, 20 splenic arteries, 7 gastroduodenal
arteries, 1 middle colic artery, and 2 pancreaticoduodenal arteries. Of these, 29 (60%) were performed for symptomatic
disease (5 ruptured aneurysms). Procedures were performed in the endovascular suite under local anesthesia with
conscious sedation (94%). The femoral artery was used as the preferential access site (90%). Coil embolization was used
for aneurysm exclusion in 96%. N-butyl-2-cyanoacrylate (glue) was used selectively (19%) using a triaxial system with a
3F microcatheter for persistent flow or multiple branches. The 30-day mortality was 8.3% (n 4). One patient died from
recurrent gastrointestinal bleeding after gastroduodenal embolization, and the remaining died of unrelated causes. All
perioperative deaths occurred in patients requiring urgent or emergent intervention in the setting of hemodynamic
instability. No patients undergoing elective intervention died in the periprocedural period. Postprocedural imaging was
performed after 77% of interventions at a mean of 16 months. Complete exclusion of flow within the aneurysm sac
occurred in 97% interventions with follow-up imaging, but coil and glue artifact complicated CT evaluation. Postembo-
lization syndrome developed in three patients (6%) after splenic artery embolization. There was no evidence of hepatic
insufficiency or bowel ischemia after either hepatic or mesenteric artery aneurysm treatment. Three patients required
secondary interventions for persistent flow (n 1) and recurrent bleeding from previously embolized aneurysms (n 2).
Conclusion:Visceral artery aneurysms and pseudoaneurysms can be successfully treated with endovascular means with low
periprocedural morbidity; however, the urgent repair of these lesions is still associated with elevated mortality rates.
Aneurysm exclusion can be accomplished with coil embolization and the selective use ofN-butyl-2-cyanoacrylate. Current
catheter-based techniques extend our ability to exclude visceral artery aneurysms, but imaging artifact hampers
postoperative CT surveillance. ( J Vasc Surg 2007;45:276-83.)Aneurysmal degeneration of the visceral branches of
the abdominal aorta is a rare and potential life-threatening
disease entity1,2 with a documented prevalence of 0.1% to
2%.3,4 The augmented use of ultrasonography and cross-
sectional body imaging for intra-abdominal pathology,
coupled with increased instrumentation of the biliary tract,
has raised the prevalence and incidental identification of
visceral artery aneurysms (VAA) and pseudoaneurysms
(VAPA).
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276Although small VAA generally remain asymptomatic,
they follow an insidious course and the risk for aneurysm
rupture and death remains real. Shanley et al5 reviewed
cases of VAA from 1985 to 1995 in the English literature,
reporting amortality rate of 21% for ruptured hepatic artery
aneurysms and 100% for ruptured celiac artery aneurysms.
VAA have been historically managed with either close
surveillance or open surgical intervention. Current open
surgical therapeutic options for VAA and VAPA include
aneurysm resection with revascularization, aneurysm liga-
tion, or end-organ resection (ie, splenectomy). Endovascular
approaches to managing VAA and VAPA (Figs 1, 2, and 3)
offer an alternative to conventional open surgery with the
benefit of low procedural morbidity andmortality. Endolu-
minal ablation of VAA and VAPA have been shown to be
highly technically successful,6 but concern of aneurysm
reperfusion during follow-up persists.7 Furthermore, be-
cause ablative endoluminal therapy of VAA and VAPA
often requires highly radiodense materials, such as glue and
aneurysm sac flow.
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and parent vessel patency may be suboptimal.
The purpose of this study was to describe our single-
center experience with the endovascular ablative manage-
ment of VAA and VAPA. Specific focus was given to
procedural techniques, rates of technical success, perioper-
ative morbidity and mortality, durability of repair, and
adequacy of postoperative imaging modalities.
PATIENTS AND METHODS
A retrospective review was performed of patients who
underwent endovascular treatment of VAA or VAPA at The
Cleveland Clinic Foundation from January 1, 1997, to July
31, 2005. During the study interval, 90 patients were
identified with VAA. Endoluminal ablation of a VAA or
VAPA was performed in 48 patients (51 procedures), rep-
resenting 53.5% of all patients diagnosed with aneurysms of
the visceral vessels. Three patients required an additional
endoluminal procedure. Demographic and clinical data
were obtained through review of physician and hospital
records.
Preoperative and postoperative imaging consisted of
computed tomography (CT), magnetic resonance imaging
(MRI) and angiography (MRA), duplex scanning, or a
combination of these. Preoperative imaging was reviewed
from captured and stored electronic images (MagicView
program, Siemens, Erlangen, Germany) to confirm the
diagnosis of VAA/VAPA.
Patients with symptomatic or asymptomatic aneurysms
of the celiac axis, superior mesenteric artery (SMA), and
inferior mesenteric artery, and their respective branches,
were included in the analysis. Patients with VAA in the
setting of aortic dissection or concomitant aortic aneurysm
were excluded. Pseudoaneurysms were distinguished from
true aneurysms by clinical and imaging criteria. Clinically,
patients with VAPA typically presented with an antecedent
history of arterial trauma, intra-abdominal or retroperito-
neal inflammation or malignancy, or biliary tract manipu-
lation. Imaging of VAPA demonstrated evidence of focal
arterial disruption in the setting of an otherwise normal
artery. Evidence of surrounding inflammation in the setting
of an irregular aneurysmal wall was also present. Patients
who underwent diagnostic angiography without the inten-
tion of endovascular treatment were excluded.
Preoperative demographic data included age, sex, and
cardiovascular risk factors (Table I). Specifically, risk factors
assessed included hypertension, hyperlipidemia, coronary
artery disease, renal insufficiency, diabetes mellitus, and
history of tobacco use. Patients were also assessed for
whether their VAA/VAPA was symptomatic, ruptured, or
hemodynamically stable at presentation.
Operative technique. Percutaneous interventions were
performed by the faculty of The Cleveland Clinic Depart-
ment of Vascular Surgery and Department of Interven-
tional Radiology in dedicated endovascular suites with
fixed imaging. The most common technique (81.3%) for
endoluminal VAA/VAPA therapy was ablation withFig 1. A, Preoperative computed tomography (CT) image dem-
onstrates a 3.0 cm distal splenic artery aneurysm in a young
woman. The splenic artery aneurysm was incidentally discovered
during an evaluation for an unrelated cause of abdominal pain. B,
Aortography with selective celiac axis imaging confirmed the pres-
ence of a splenic artery aneurysm.A shaped 6F sheathwas placed into
the ostium of the celiac axis. A 5 F hydrophilic catheter was then used
with a hydrophilic 0.035-inch wire to selectively gain access into the
splenic artery. A 3F microcatheter was advanced thru the 5F catheter
over a 0.018-inch wire. N-butyl-2-cyanoacrylate (N-BCA), diluted
1:3 with ethiodized oil, was used to occlude the outflow vessel.
Coils were deployed in the aneurysm sac and in the inflow vessel to
completely exclude the aneurysm. Angiography after deployment
of coils andN-BCA confirms successful exclusion of the aneurysm
sac and absence of flow within outflow vessels. C, Postoperative
CT demonstrates coil and glue artifact with no gross evidence ofcoils. In all cases, ablative therapy of the outflow tract, the
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N-butylcyanoacrylate (N-BCA) glue (Cordis Neurovascu-
lar, Miami, Fla) or a combination of coils and N-BCA was
used for ablation in 4.2% and 15% of cases, respectively. The
United States Food andDrug Administration has approved
N-BCA for the preoperative ablation of intracranial arterio-
venous malformations, and we have found a benefit in
Fig 2. An elderly man presented with signs of hypovolemic shock
and abdominal pain. After initial stabilization, a computed tomog-
raphy (CT) scan demonstrated the presence of a large mesenteric
hematoma with a contrast blush arising from a mesenteric branch.
A, Selective visceral angiography identified a fusiform aneurysm of
the left branch of the middle colic artery. B, A 6F sheath was
placed into the ostium of the superior mesenteric artery. A 5F
hydrophilic catheter was advanced to the origin of the middle
colic artery. A 3F microcatheter with 0.018-inch wire was used to
selectively cannulate the middle colic artery and its left branch. The
microcatheter was advanced through the aneurysm into its outflow
vessel. N-butyl-2-cyanoacrylate (N-BCA) and 0.018-inch coils
were deployed within the aneurysm sac and N-BCA was instilled
within the inflow vessel. C, Postoperative imaging demonstrated a
patent superior mesenteric artery and middle colic artery. The left
branch was not visualized because it was completely ablated. Coils
and glue are evident, however.extending its use to the treatment of VAA and endoleaksafter endoluminal stent grafting. Depending on the desired
rate of polymerization, N-BCA is diluted with ethiodized
oil, a polymerization-retardant. Specifically, when emboli-
zing a vessel with high rates of blood flow, we desired quick
in vivo polymerization and a ratio of 1:1 oil toN-BCA was
used. In situations where the microcatheter tip was posi-
tioned distant from the desired site of polymerization, a
greater volume of ethiodized oil (ie, 2:1, 3:1 dilutions) was
added to delay glue polymerization. Although the decision
to use coils or N-BCA, or both, was physician-dependent,
the glue was routinely used when access into the aneu-
rysm’s outflow vessel was unattainable.
Conscious sedation with local anesthetic was used in 45
of 48 interventions. Three patients required general anes-
thesia in the setting of hemodynamic instability secondary
to blood loss from symptomatic disease. Endovascular ac-
cess for all procedures was through the femoral artery
(89.6%) or brachial artery (10.4%). A 5F (56.3%) or 6F
sheath (29.2%) was used in most cases, and a 7F sheath was
used in the rest. A shaped guiding catheter was used selec-
tively in the ostia of the visceral vessel in instances in which
a sheath could not successfully be engaged. Intravascular
ultrasound was required in one patient to assist in identifi-
cation of a celiac axis pseudoaneurysm that was not clearly
demonstrated on selective angiography.
A triaxial endovascular system with a 3F microcatheter
was used in 64.6% of interventions and was specifically
required for the deployment of N-BCA or 0.018-inch
intravascular coils. We have also found a microcatheter
system useful for interventions upon the distal aspect of
an arterial bed and for the selective embolization of an
aneurysm/pseudoaneurysm cavity with preservation of the
proximal parent artery.
An uncovered self-expanding nitinol stent was selec-
tively placed to preserve flow within a visceral vessel and to
exclude coils placed within aneurysmal artery from en-
croaching and compromising a nondiseased parent artery
(n 2) and to treat hemodynamically significant dissection
resulting from visceral vessel cannulation (n  1).
Percutaneous mechanical thrombectomy of the celiac
axis and femoral artery was required during two separate
procedures to recanalize an acute procedure-related occlu-
sion during hepatic artery embolization. Owing to the rich
collateral network between the celiac axis and SMA, postem-
bolization imaging through both arterial trees was routinely
performed to confirm exclusion of the aneurysmal segment.
All patients with elective repair underwent systemic
anticoagulation with heparin to achieve an activated clot-
ting time of 250 seconds. Patients with rupture received
small doses (2 to 3000 units) of heparin after selective
visceral cannulation. Three patients with hemodynamic
instability received no anticoagulation.
Technical success was defined as the successful deploy-
ment of coils or glue (or both) within the intended artery,
exclusion of the aneurysmal arterial segment without evi-
dence of contrast extravasation, and cessation of hemor-
rhage, if originally present. In instances of aneurysmal
disease of second-order or third-order branches, technical
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with preservation of flow within the intended parent artery.
In three cases, VAA or VAPA with very sluggish flow in the
fully anticoagulated state were considered successfully ex-
cluded.
Data analysis and statistical methods. Periprocedural
data, associated morbidity, and mortality 30 days of the
Fig 3. A middle-aged man, who had previously undergone aor-
tohepatic bypass grafting for an occluded celiac axis, presented
with an incidentally discovered large pancreaticoduodenal aneu-
rysm.A,His computed tomography (CT) scan demonstrated a large
aneurysm arising from a branch of the superior mesenteric artery
(SMA). B, CT shows the aneurysm collaterilizing with the superior
pancreaticoduodenal arcade of the gastroduodenal artery (GDA). He
underwent selective angiography of the aortohepatic bypass and
SMA, demonstrating filling of the aneurysm via both mesenteric
vessels. A 6F sheath was first placed into the ostium of the aorto-
hepatic bypass, with subsequent passage of a hydrophilic 5F cath-
eter into the distal aspect of the bypass. Selective cannulation of the
GDA was then performed with a microcatheter and 0.014-inch
wire. Glue ablation of the aneurysm sac, as well as its inflow via the
GDA and inferior pancreaticoduodenal vessels, was achieved. C,
Postoperative imaging confirmed successful ablation of the aneu-
rysm with a patent SMA.procedure were determined. Follow-up documentation ofsuccessful aneurysm ablation included resolution of gastro-
intestinal bleeding/hemobilia in such symptomatic cases
and absence of flow on follow-up CT or MRI/MRA.
Postoperative imaging was assessed for sac flow, aneurysm
size change, adequacy of end-organ perfusion, and severity
of coil or N-BCA artifact. Postprocedural imaging artifact
was graded by severity: grade 1, minor with no radiopaque
scatter; grade 2, moderate with mild radiopaque scatter
beyond the region treated; and grade 3, severe with signif-
icant radiopaque scatter. The interval of follow-up at The
Cleveland Clinic Foundation was recorded and averaged
15.6 months (range, 1 to 75 months).
RESULTS
During the study period, 48 patients (mean age, 58
years) underwent endovascular management of VAA or
VAPA. The anatomic distribution of aneurysms treated
included 12 hepatic artery aneurysms (20%), 3 celiac axis
aneurysms (6.3%), 2 left gastric aneurysms (4.2%), 2 SMA
branch aneurysms (4.2%), 20 splenic artery aneurysms
(41.7%), and 9 gastroduodenal/pancreaticoduodenal ar-
tery aneurysms (18.8%). Overall, 28 (58%) of the interven-
tions were for pseudoaneurysmal pathology. In 65% of
patients, treatment was required for symptomatic disease,
including rupture, pain, gastrointestinal bleeding, and/or
hemobilia. The symptoms at presentation and the distribu-
tion of lesions amongst the various arterial beds (Fig 4)
were significantly different between VAA and VAPA. Of
the 48 patients, 22 (46%) underwent urgent or emergent
procedures.
Treatment was for VAA in 42% of patients, and splenic
artery aneurysms comprised 75% of true aneurysms in our
study. The mean size of all VAA was 2.4 cm. At presenta-
tion, 30% of patients with VAA were symptomatic, and one
third of these warranted urgent intervention. Only one case
of hemodynamic instability secondary to a VAA was noted,
however. Asymptomatic VAA (30%) were incidentally
identified and treated on the basis of dimensional criteria.
Two true aneurysms presented with rupture: one was a
2.5-cm hepatic artery aneurysm, and the other was a middle
Table I. Demographic and clinical factors for 48 patients
undergoing endovascular management of visceral artery
aneurysms and pseudoaneurysms
Variable* No. patients (%)
Male sex 29 (60)
Hypertension 21 (44)
Hyperlipidemia 10 (21)
Coronary artery disease 12 (25)
Diabetes mellitus 6 (13)
Tobacco use† 5 (10)
Renal dysfunction‡ 3 (6)
*Mean patient age, 58.1 years.
†Includes only current smokers.
‡Serum creatinine 1.5 mg/dL or dialysis-dependent.colic artery aneurysm of unknown size.
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symptomatic at presentation. Most of the visceral false
aneurysms presented with gastrointestinal bleeding or he-
mobilia, such that 92% of these patients required urgent
intervention. The mean size for all false aneurysms treated
was 3.0 cm. Three pseudoaneurysms (1 SMA, 1 celiac,
1 splenic) presented with rupture.
Technical success was achieved in 47 (98%) of 48 of
procedures. One technical failure occurred during treat-
ment of a celiac artery aneurysm distal to an ostial occlu-
sion. Retrograde perfusion of a 2.8-cm aneurysm through
the gastroduodenal arcade and splenic artery warranted
intervention. Upon completion of the procedure, persis-
tent flow through the aneurysm was identified. Follow-up
imaging 3 weeks later demonstrated a slight decrease in
aneurysm size. A secondary intervention was attempted to
ablate the aneurysm sac, but was unsuccessful and aborted
due to diminishing sac size.
Interventionsonthehepaticarterial tree,gastroduodenal/
pancreaticoduodenal arteries, and left gastric artery were
performed primarily for pseudoaneurysms related to percu-
taneous biliary catheters, intravascular chemoembolization
catheters, local infectious and inflammatory processes, or
iatrogenic operative injury.
The 30-day operative mortality was 8.3%. Two unsta-
ble patients with extensive hepatobiliary surgery died after
embolization: one died from recurrent bleeding in the
setting of unresectable carcinoma. A third patient, treated
for a ruptured hepatic artery aneurysm, died after a sub-
arachnoid hemorrhage caused from a ruptured anterior
cerebral artery aneurysm. A fourth patient died from com-
plications from an underlying intra-abdominal malignancy
after a technically successful endovascular treatment of an
acutely ruptured 2-cm jejunal artery pseudoaneurysm. The
four patients who died in the perioperative period were
among the 22 patients who required urgent or emergent
intervention because of hemodynamic instability attribut-
able to a symptomatic VAA or VAPA (18% mortality rate).
There were no deaths amongst patients electively treated
for VAA/VAPA (Table II).
Access-related complications developed in two pa-
tients. One sustained a documented groin hematoma not
requiring transfusion. In the other patient, access-related
femoral artery thrombosis occurred and was treated with
percutaneous mechanical thrombectomy. This patient also
developed a retroperitoneal hematoma ipsilateral to the
access site. Both instances of access-related complications
occurred during urgent therapy for symptomatic VAPA.
There were no instances of femoral or brachial artery
pseudoaneurysms.
Excluding the four patients who died in the periopera-
tive period, the mean length of stay for patients undergoing
endovascular VAA or VAPA ablation was 5.3 days (range,
1 to 51 days). The mean lengths of stay were 1.8 days after
intervention for VAA and 7.8 days after VAPA treatment.
The length of stay for patients with VAPA was extended
owing to complications attributable to recent surgeries or
significant comorbidities warranting admission.Three patients (6.3%) required secondary interventions.
Oneunsuccessful secondary interventionwas attempted in the
case of a celiac axis aneurysm, as previously described. A
second patient, with Caroli disease and percutaneous biliary
catheters, required coil embolization for hemobilia emanating
from a third-order hepatic artery pseudoaneurysm. He pre-
sented 2 weeks later with recurrent gastrointestinal bleeding
and hemobilia. Repeat angiography demonstrated migration
of the recently placed coils into the pseudoaneurysm sac
associated with sac growth. Successful recoiling proximal to
the diseased segment was performed. Another secondary in-
terventionwas needed in a patient with a history of orthotopic
hepatic transplantation who underwent coil embolization of a
bleeding hepatic artery pseudoaneurysm. She presented 2
years later with rebleeding through the previously coiled
segment that necessitated repeat endovascular ablation.
No access site complications resulted from these reinter-
ventions.
Postprocedural imaging was available in 37 (77%) of
the 48 patients. This consisted of angiography (n  1),
MRI/MRA (n  3), and CT (n  33). Two patients also
underwent adjunctive duplex imaging. The mean length of
radiologic follow-up was 15.6 months (range, 1 day to 75
months). Flow through the previously treated aneurysm sac
was identified in only one patient 3 weeks after emboliza-
tion; thus, aneurysm exclusion was confirmed in 36
(97.3%) of 37 postoperative studies. No patient demon-
strated gross evidence of aneurysm sac growth or endoleak.
In addition, no significant decrease in aneurysm sac size
post-intervention was noted on follow-up.
Six end-organ infarcts, all within the splenic bed, were
identified. Volumetric analysis determined the mean infarct
size was 19%. Two additional patients displayed evidence
of splenic atrophy after embolization without evidence of
splenic infarcts. Splenic size was preserved in all cases of
splenic artery embolization with postintervention splenic
infarct. Of note, all splenic changes were identified during
the review of images for this retrospective study. None of
these patients exhibited any hematologic or infectious com-
plication or other evidence of clinical sequelae from the
Fig 4. Distribution of visceral artery aneurysms (VAA) and vis-
ceral artery pseudoaneurysms (VAPA) amongst the various vis-
ceral arterial beds. (SMA, Superior mesenteric artery.)changes in spleen volume. No instances of hepatic infarc-
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No patients were identified with visceral artery aneurysms
of other arterial beds.
None of the 37 patients with postoperative follow-up
had hepatic insufficiency or intestinal ischemia attributable
to aneurysm ablation. Postembolization syndrome devel-
oped after endovascular ablation of a splenic artery aneu-
rysm in three patients. In one case, there was evidence of
distal embolization ofN-BCA into the splenic hilumwith the
presence of multisegmental splenic infarction. Another pa-
tient had evidence of splenic atrophy without infarcts. The
third patient demonstrated evidence of multiple underper-
fused segments of spleen. These patients had left-sided ab-
dominal discomfort and diaphragmatic irritation that re-
solved over time. Despite evidence of splenic ischemia and
postembolization syndrome in nearly 40% of patients with
treated splenic VAA/VAPA, no patient demonstrated he-
matologic changes related to splenic insufficiency.
Five of 33 CT scans were deemed to have grade 1
artifact, 11 had grade 2 artifact, and 17 had grade 3 artifact.
Grade 1 artifact was noted in one MRI/MRA, and grade 3
artifacts were noted in two. No association could be iden-
tified between coils and N-BCA and the degree of artifact.
DISCUSSION
Visceral artery aneurysms and pseudoaneurysms are
rare but potentially lethal disease entities. The clinical sig-
nificance of identifying and appropriately treating these pa-
thologies stems from an effort to prevent aneurysm rupture
into the peritoneal cavity or hepatobiliary and gastrointestinal
tract. The increased application of high-resolution imaging
techniques has resulted in increased identification of VAAs.
In addition, increased manipulation of the biliary tree
through percutaneous and endoscopic techniques, as well
as placement of intravascular chemoembolization cathe-
ters, has resulted in a greater incidence of pseudoaneurys-
mal degeneration of the visceral vessels. Arterial trauma
related to laparoscopic treatment of intra-abdominal and
retroperitoneal pathologies has also contributed to the
increasing incidence of VAPA.
Although open surgical repair of these aneurysms re-
mains the gold standard, endoluminal techniques may offer
Table II. Distribution of elective and urgent intervention
associated perioperative results
Arterial bed Urgent vs elective No.
Mean siz
(mm)
Splenic Urgent 3 63
Elective 17 28
Celiac axis branches* Urgent 9 22
Elective 5 32
SMA Urgent 1 20
Elective 1 22
Hepatic Urgent 9 16
Elective 3 53
*Except splenic/hepatic.a viable alternative for therapy. Pseudoaneurysms of thesplenic artery from pancreatic inflammation, mesenteric
artery owing to abdominal sepsis or operative injury, and
intrahepatic arterial tree from catheter or stent trauma pose
a unique challenge to management:
1. Open surgical repair in these hostile environments is
often fraught with technical difficulty and potentially
elevates the associated morbidity of the repair.
2. This patient cohort often presents with significant comor-
bid conditions (pancreatitis, hepatobiliary disease) that
elevate the risk of major operative vascular reconstruction.
3. Because many of these patients present acutely with
bleeding or rupture, risk-stratification, and medical op-
timization may not be feasible.
As such, minimally invasive endoluminal techniques may
offer a distinct advantage to conventional repair.
Most of the literature on open repair of visceral artery
aneurysms is limited to small series and case reviews. Owing
to the relative paucity of visceral artery aneurysms, out-
comes for open repair are typically not distinguished by
arterial bed. Furthermore, most of the existing studies have
not made a distinction between true aneurysms and false
aneurysms. This bears significance in assessing operative
morbidity and mortality, because the risk of aneurysm
rupture is a function of the visceral vessel involved as well as
aneurysmal vs pseudoaneurysmal pathology.
Mortality rates after the elective treatment of visceral
artery aneurysms has been documented as approximately
5%.8 Conventional treatment of ruptured visceral artery
aneurysms is associated with significant mortality. In the
setting of splenic artery aneurysm rupture, open recon-
struction is associated with operative mortality rates of 10%
to 25%.9 Perioperative death rates may be even greater
during conventional treatment of ruptured hepatic, SMA,
and celiac axis aneurysms.3,10 The use of minimally invasive
techniques may provide a survival benefit not only for
elective interventions but also for urgent procedures in
patients presenting with visceral aneurysm rupture.
Splenic artery aneurysms comprised 42% of aneurysms
treated in this study. The preponderance of aneurysmal
disease of the splenic bed is not unexpected. In fact, true
splenic artery aneurysms account for 60% of all splanchnic
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eaneurysms.11 Because variations in hormonal milieu are
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it is not surprising that splenic artery aneurysms are more
common in women than in men. Our study did not dem-
onstrate the generally reported fourfold greater incidence
of splenic artery aneurysms in women, but women did
account for 60% of our cohort.
A concern exists for splenic insufficiency after main
splenic artery embolization. It was of interest that evidence
of splenic ischemia, such as infarcts or significant atrophy,
was noted in 40% of cases after splenic artery ablation, but it
seemed to have minimal clinical sequelae. This was primar-
ily noted after embolization of distal splenic artery or
hilar/intrasplenic aneurysms.
Conventional repair of these lesions, with its attendant
morbidity, would typically require distal splenic artery ligation
or splenectomy. Recently, stent graft repair of splenic artery
aneurysms has received increasing attention.12,13 It offers the
potential benefit of maintaining splenic perfusion while ex-
cluding the aneurysm, thereby eliminating the risk of rupture.
Our review of postoperative imaging suggested that the
natural history of true splenic artery aneurysms may also
involve elongation and increasing tortuosity of the vessel. In
such instances, delivery of a covered stent to a mid-splenic or
distal-splenic artery aneurysmmay be technically unattainable
because of existing device limitations. As such, endovascular
stent grafting of these lesionsmay be confined to the proximal
splenic artery. Further assessment of this mode of therapy is
warranted for the treatment of splenic artery aneurysms and
aneurysmal degeneration of other visceral beds.
Technical success was achieved in 98% of our interven-
tions. This is in concordance with other recent reports
documenting the high rates of technical success attainable
with the endovascular management of VAA.6 Our study is
unique owing to the significant percentage of patients
treated for distal extrahepatic, intrahepatic, gastroduodenal/
pancreaticoduodenal, and intrasplenic/hilar lesions. To
achieve such rates of technical success, aneurysmal exclu-
sion requires intraoperative high-resolution imaging, tech-
nical expertise in visceral vessel cannulation, comfort with
use of a triaxial system, and knowledge in the proper
preparation and deployment ofN-BCA. AlthoughN-BCA
is currently approved for the presurgical endoluminal abla-
tion of cerebral arteriovenous malformations, we have
found invaluable the extension of its use to treat endoleaks
after endovascular aortic aneurysm repair and in the treat-
ment of visceral artery aneurysms.
Unlike coils, which are solid, N-BCA is deployed in
liquid form before polymerization. This feature is beneficial
in ablating aneurysms with multiple outflow vessels or in
the setting of persistent aneurysm flow despite coiling. The
use of N-BCA requires meticulous detail in preparation.
Because it polymerizes on contact with tissue and blood,
care must be exercised to reduce the risk of polymerization
ex vivo or within the catheter system before deployment.
Realizing the potential for microcatheter polymeriza-
tion, we routinely use a triaxial system with a 3F microcath-
eter. In such a system, a sheath or guiding catheter is placed
into the visceral vessel of interest. A 4F or 5F catheter istelescoped through the sheath or guiding catheter, through
which a microcatheter is used for glue deployment. If the
glue polymerizes within the microcatheter, rapid exchange
of microcatheters is possible without losing visceral vessel
access. A 3F microcatheter has also been useful in the
exclusion of aneurysms of the intrahepatic circulation and
distal arterial beds, where access with a 5F catheter may be
unsafe or technically unattainable.
We noted a perioperative mortality rate of 8.3%, which
is higher than previously reported for the endoluminal
ablation of visceral artery aneurysms.14 All patients who
died in the perioperative period had required emergent
intervention because of hemorrhage. No mortalities oc-
curred after elective aneurysm ablation. This underscores a
critical finding that the endovascular management of VAA/
VAPA in the elective setting has a low rate of perioperative
morbidity and mortality. However, the emergent treat-
ment of these lesions, similar to open reconstruction, is
associated with elevated rates of procedural morbidity.
This study represents, to our knowledge, the largest re-
view of endoluminally excluded visceral artery aneurysms.
Radiologic surveillance after ablation highlights the mid-term
durability of endovascular aneurysm ablation.No patient with
VAA sustained a delayed aneurysm rupture during follow-up.
In addition, no patient demonstrated evidence of aneurysm
sac growth on postoperative surveillance. Conversely, aneu-
rysm sac shrinkage was also not observed. The use of emboli-
zation materials to fill the aneurysm sac likely causes the
aneurysm to mold itself to its internal contents.
A dilemma is posed with current ablative techniques,
however. Although a fluoroscopically identifiable agent is
required for accurate deployment, current radiopaque
agents create a significant amount of radiologic artifact on
postoperative imaging. Assessment of aneurysm sac growth
is thereby hampered. The development of fluoroscopically
identifiable ablative agents that are not highly radiodense
on noninvasive radiologic imaging is needed. In addition,
investigation should be performed of alternative means of
surveillance, such as color-flow duplex.
Our study has various limitations. Inherent to its retro-
spective design, we are unable to draw conclusions about
treatment paradigms for VAA or optimal modes of abla-
tion. Guidelines for size criteria for intervention also cannot
be extrapolated from our study. We generally treat all
symptomatic aneurysms, visceral aneurysms in women of
gestational age, and aneurysms sized 2 cm, but these
guidelines have been extrapolated from literature specific to
true splenic artery aneurysms. Just as the mortality after
rupture of aneurysms of different arterial trees is different,
the risk of rupture may also vary between visceral vessels.
Pseudoaneurysms must also be evaluated separately
from true aneurysms. Tessier et al15 reviewed their experi-
ence with splenic artery pseudoaneurysms during an 18-
year period. They did not identify pseudoaneurysm size as
being a predictor of risk for rupture because both small (0.3
cm) and large (17 cm) pseudoaneurysms had ruptured in
their series. It has been our protocol to treat all visceral
artery pseudoaneurysms irrespective of size.
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vascular ablation with open reconstruction are required to
make firm recommendations for protocols of therapy.
Given the paucity of visceral artery aneurysms, however, the
distinct behavior between aneurysms of different visceral
vessels and the malignant natural history of pseudoaneu-
rysms, such studies would likely be not be realistic or
fulfilling. Longer-term follow-up with larger patient co-
horts are necessary to elucidate the ultimate role of endolu-
minal therapy in the treatment of visceral artery aneurysms
and pseudoaneurysms.
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Dr Paul Van Bemmelen (Philadelphia, Pa). Did you rule out
mycotic aneurysms in this population? Were there any comparable
open treatments done during this time period, or is everybody
treated endovascularly?
Dr Nirman Tulsyan. During the study period, we identified
90 patients with visceral artery aneurysms. Nineteen patients un-
derwent open treatment. The choice of therapeutic modality was
primarily operator-dependent given the retrospective nature of this
paper. Of the patients who presented with true aneurysms, none
clinically manifested prodromal symptoms or signs to suggest
presence of a mycotic aneurysm or microbial arteritis with aneu-
rysmal degeneration.
With respect to the pseudoaneurysms, the majority of patients
presented with signs of systemic inflammation, whether that be
intra-abdominal sepsis or retroperitoneal inflammation. While it is
possible that these lesions were mycotic, we did not make the
distinction nor did it change our management.
Dr Grayson Wheatley (Phoenix, Ariz). How do you ap-
proach visceral artery aneurysms with respect to embolization
versus excluding with an endoluminal graft? I would think that
some of these visceral aneurysms would be amenable to exclusion
rather than embolization.
Dr Tulsyan. Subsequent to the end of the study period, we’ve
actually treated multiple patients with stent grafts in an effort to
maintain parent artery patency. With regard to true aneurysms, we
have noted that use of stent grafts is a function of the location of the
aneurysm. In the setting of a splenic artery aneurysm, for example,
distal, hilar, or intrasplenic lesions would be technically difficult toAdditionally, we have noted a significant amount of elonga-
tion and tortuosity of parent arteries that occurs in the setting of
visceral artery aneurysms. In attempting to treat a distal vessel it
may be difficult to deliver your device. It may be feasible, however,
in the setting of more proximal lesions.
Dr. Robert Cambria (Bangor, Me). Several small series have
indicated association of stenosis of major visceral vessels with
pseudoaneurysms or, rather, true aneurysms of the visceral seg-
ments. Did you notice this association and did it impact in any way
on your approach? And finally, were there any aneurysms that you
attempted to treat but could not?
Dr Tulsyan. In reviewing all of the imaging, we actually did
not find a high incidence of aortoiliac occlusive disease. As such,
this did not alter our treatment.
There was one technical failure in our series. This occurred in
a patient who underwent successful treatment of a celiac axis
aneurysm but had persistent flow within the celiac trunk after
embolization. On follow-up imaging, there was a decrease in aneu-
rysm size. However, since there was significant flow on completion
angiography, a secondary intervention was performed via the SMA.
Dr Kenneth Cherry (Charlottesville, Va). When you have an
aneurysm that involves either the SMA or one of its major
branches, are you at all hesitant about providing an occlusive
solution as opposed to one that insures continued patency?
Dr Tulsyan. All the patients in our study with mesenteric
aneurysms were treated for lesions of branch vessels. We would be
very hesitant to ablate a main trunk aneurysm of the SMA, for
example, since the risk and sequelae of end-organ ischemia is
significant in this situation. We would elect for alternative therapy
in this instance.
